A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
10 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to evaluate FMC-376 monotherapy and in combination with pembrolizumab in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.
Sponsor: Frontier Medicines Corporation
You may qualify if…
- ✓ Histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumors with KRAS G12C mutation
- ✓ Received and progressed or been intolerant to prior standard therapy OR standard therapy is considered inappropriate OR an investigational agent is considered standard of care
- ✓ NSCLC Participants (in the first-line advanced or metastatic setting who refused standard therapy or standard therapy was considered inappropriate)
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- ✓ Adequate hematological, renal, and hepatic function
- ✓ Agrees not to participate in another interventional study while receiving study drug
- ✓ For patients receiving FMC-376 in combination with pembrolizumab: No history of autoimmune disease, and no history of immune-related adverse events or hepatitis
You may not qualify if…
- ✕ Leptomeningeal disease or carcinomatous meningitis
- ✕ Clinically significant toxicity resulting from prior cancer therapies
- ✕ Known or suspected hypersensitivity to FMC-376 or any components of the study drug
- ✕ Condition that would interfere with study drug absorption
- ✕ Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data
- ✕ For patients receiving FMC-376 in combination with pembrolizumab: Has severe hypersensitivity (≥ Grade 3) to pembrolizumab, history of radiation-related toxicities, or history of non-infectious pneumonitis.
Where it's recruiting
La Jolla · Orange · San Francisco
Lake Mary
Dyer
Fairway
Boston
Detroit
Philadelphia
Houston · Kingwood · San Antonio
West Valley City
Fairfax
Source: ClinicalTrials.gov · NCT06244771 · last updated 2026-10-19